Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond.
Aged
Aged, 80 and over
Breast Neoplasms
/ diagnosis
COVID-19
/ epidemiology
Female
Humans
Interdisciplinary Communication
Medical Oncology
/ methods
Neoplasm Metastasis
/ prevention & control
Neoplasm Recurrence, Local
/ prevention & control
Pandemics
Receptor, ErbB-2
/ metabolism
SARS-CoV-2
/ physiology
United States
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
07
04
2020
revised:
18
05
2020
accepted:
20
05
2020
pubmed:
26
5
2020
medline:
4
5
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Caring for older patients with breast cancer presents unique clinical considerations because of preexisting and competing comorbidity, the potential for treatment-related toxicity, and the consequent impact on functional status. In the context of the COVID-19 pandemic, treatment decision making for older patients is especially challenging and encourages us to refocus our treatment priorities. While we work to avoid treatment delays and maintain therapeutic benefit, we also need to minimize the risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposures, myelosuppression, general chemotherapy toxicity, and functional decline. Herein, we propose multidisciplinary care considerations for the aging patient with breast cancer, with the goal to promote a team-based, multidisciplinary treatment approach during the COVID-19 pandemic and beyond. These considerations remain relevant as we navigate the "new normal" for the approximately 30% of breast cancer patients aged 70 years and older who are diagnosed in the United States annually and for the thousands of older patients living with recurrent and/or metastatic disease.
Identifiants
pubmed: 32449757
pii: 5843796
doi: 10.1093/jnci/djaa079
pmc: PMC7313961
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-359Subventions
Organisme : NCI NIH HHS
ID : K12 CA001727
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA227615
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.